Skip to main content

Research News

 

Clinical courses

 

Clinical courses

  • How sensory gamma rhythm stimulation clears amyloid in Alzheimer’s mice

    Studies at MIT and elsewhere are producing mounting evidence that light flickering and sound clicking at the gamma brain rhythm frequency of 40 Hz can reduce Alzheimer’s disease (AD) progression and treat symptoms in human volunteers as well as lab mice.

  • Heart disease research challenges one size fits all aspirin guidelines

    Heart disease researchers have identified a group of patients in whom international guidelines on aspirin use for heart health may not apply.

    In a study published in the renowned medical journal Circulation, the findings of a review of data from three clinical trials challenge current best practice for use of the drug for primary prevention of heart disease or stroke - otherwise known as atherosclerotic cardiovascular disease.  

  • 100 Rs tablet prevents spread of cancer, breakthrough research by Indian Scientists

    The breakthrough research by TATA memorial centre scientists who have developed a tablet which reduces side effects of cancer treatment and prevent resurgence or relapse of cancer said Dr Rajendra Badwe, Director of the Tata Memorial Centre in an interview with NDTV. The said tablet will be available at an affordable price of Rs. 100 a tablet.

  • Compounds in female ginseng could lead to new osteoporosis treatments

    With ever-increasing life expectancy comes the challenge of treating age-related disorders such as osteoporosis. Although there are effective drugs for treating this metabolic bone disease, they can be expensive and have side effects, limiting their availability to some people. In the search for alternative drug candidates, researchers reporting in ACS Central Science have discovered and fully replicated a compound from a botanical source, female ginseng, that had potent anti-osteoporotic activity in cellular tests.

  • Drug limits dangerous reactions to allergy-triggering foods : study of kids finds

    A drug can make life safer for children with food allergies by preventing dangerous allergic responses to small quantities of allergy-triggering foods, according to a new study led by scientists at the Stanford School of Medicine. 

    The research was published Feb. 25 in the New England Journal of Medicine. The findings suggest that regular use of the drug, omalizumab, could protect people from severe allergic responses, such as difficulty breathing, if they accidentally eat a small amount of a food they are allergic to.

  • Researchers are using RNA in a new approach to fight HIV

    Society learned about the value of mRNA during the COVID-19 pandemic when we saw scientists and medical professionals harness its power to deliver a vaccine for the virus within a year.

  • Research Shows Possible Risks of Too Much Niacin

    For years, vitamin B3, better known as niacin, has been added to many of the foods we eat every day.

  • 275 Million New Genetic Variants Identified in NIH Precision Medicine Data

    Researchers have discovered more than 275 million previously unreported genetic variants, identified from data shared by nearly 250,000 participants of the National Institutes of Health’s All of Us Research Program. Half of the genomic data are from participants of non-European genetic ancestry. The unexplored cache of variants provides researchers new pathways to better understand the genetic influences on health and disease, especially in communities who have been left out of research in the past.

  • Study Finds New Inhalable Therapy is a Big Step Forward in Lung Cancer Research

    Lung cancer is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines, which are small signaling proteins, such as interleukin-12 (IL-12), have demonstrated considerable potential as robust tumor suppressors. However, their applications are limited due to a multitude of severe side effects.

  • New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial

    The phase 3 clinical trial, published today in JAMA Oncology and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer associated with exposure to asbestos and which has limited therapeutic options. The trial found that a combination treatment of traditional chemotherapy with a new drug, ADI-PEG20, increased the median survival of participants by 1.6 months, and quadrupled the survival at 36 months, compared to placebo-chemotherapy.

Subscribe to Research News